Renalytix (LON:RENX) Trading Up 13% – Still a Buy?

Renalytix Plc (LON:RENX) was up 13% during mid-day trading on Thursday . The company traded as high as GBX 8.50 ($0.11) and last traded at GBX 8.48 ($0.11). Approximately 182,612 shares traded hands during mid-day trading, a decline of 60% from the average daily volume of 458,737 shares. The stock had previously closed at GBX 7.50 ($0.10).

Renalytix Trading Down 3.0 %

The stock has a market capitalization of £13.27 million, a price-to-earnings ratio of -33.33 and a beta of 2.10. The company has a debt-to-equity ratio of 173.95, a quick ratio of 2.42 and a current ratio of 0.53. The business has a 50-day moving average of GBX 9.33 and a 200-day moving average of GBX 15.61.

Insider Buying and Selling at Renalytix

In other Renalytix news, insider Christopher H. B. Mills sold 83,696 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of GBX 8 ($0.10), for a total transaction of £6,695.68 ($8,693.43). 35.74% of the stock is owned by company insiders.

Renalytix Company Profile

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.